July 8, 2020

Winnipeg
27° C, A few clouds

Full Forecast

Advertisement

Advertise With Us

Gilead's $2,340 price for coronavirus drug draws criticism

The Free Press has made this story available free of charge so everyone can access trusted information on the coronavirus.

Support this work and subscribe today

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday, June 29 for remdesivir, and said the price would be $3,120 for patients with private insurance. It will sell for far less in poorer countries where generic drugmakers are being allowed to make it. (AP Photo/Ben Margot, File)

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday, June 29 for remdesivir, and said the price would be $3,120 for patients with private insurance. It will sell for far less in poorer countries where generic drugmakers are being allowed to make it. (AP Photo/Ben Margot, File)

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

"We’re in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic," Gilead’s chief executive, Dan O’Day, told The Associated Press.

"We believe that we had to really deviate from the normal circumstances" and price the drug to ensure wide access rather than based solely on value to patients, he said.

However, the price was swiftly criticized; a consumer group called it "an outrage" because of the amount taxpayers invested toward the drug's development.

The treatment courses that the company has donated to the U.S. and other countries will run out in about a week, and the prices will apply to the drug after that, O'Day said.

In the U.S., federal health officials have allocated the limited supply to states, but that agreement with Gilead will end after September. They said Monday that the government has secured more than 500,000 additional courses that Gilead will produce starting in July to supply to hospitals through September, and stressed that that does not mean the government actually was acquiring that much, just ensuring the availability.

"We should have sufficient supply ... but we have to make sure it’s in the right place at the right time," O’Day said

In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug; two countries are doing that for around $600 per treatment course.

Remdesivir’s price has been highly anticipated since it became the first medicine to show benefit in the pandemic, which has killed more than half a million people globally in six months.

The drug, given through an IV, interferes with the coronavirus’s ability to copy its genetic material. In a U.S. government-led study, remdesivir shortened recovery time by 31% — 11 days on average versus 15 days for those given just usual care. It had not improved survival according to preliminary results after two weeks of followup; results after four weeks are expected soon.

The Institute for Clinical and Economic Review, a non-profit group that analyzes drug prices, said remdesivir would be cost-effective in a range of $4,580 to $5,080 if it saved lives. But recent news that a cheap steroid called dexamethasone improves survival means remdesivir should be priced between $2,520 and $2,800, the group said.

"This is a high price for a drug that has not been shown to reduce mortality," Dr. Steven Nissen of the Cleveland Clinic said in an email. "Given the serious nature of the pandemic, I would prefer that the government take over production and distribute the drug for free. It was developed using significant taxpayer funding."

Peter Maybarduk, a lawyer at the consumer group Public Citizen, called the price "an outrage."

"Remdesivir should be in the public domain" because the drug received at least $70 million in public funding toward its development, he said.

"The price puts to rest any notion that drug companies will ‘do the right thing’ because it is a pandemic," Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in New York said in an email. "The price might have been fine if the company had demonstrated that the treatment saved lives. It didn’t."

While it may be a sticker shock for many, "from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value," Dr. David Boulware, an infectious disease specialist at the University of Minnesota, said in an email.

O’Day said that shortening hospitalization saves about $12,000 per patient. Gilead says it will have spent $1 billion on developing and making the drug by the end of this year. Gilead shares rose 64 cents to $75.22 in late-morning trading.

The drug has emergency use authorization in the U.S. and Gilead has applied for full approval.

Jefferies pharmaceuticals analyst Michael Yee wrote to investors that Gilead’s price was a bit above what stock brokers were expecting. He said that at that price, analysts expect Gilead to make $525 million on remdesivir sales this year and $2.1 billion next year.


Marilynn Marchione can be followed on Twitter: @MMarchioneAP


AP Business Writer Linda A. Johnson contributed to this report.


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Advertisement

Advertise With Us

Your support has enabled us to provide free access to stories about COVID-19 because we believe everyone deserves trusted and critical information during the pandemic.

Our readership has contributed additional funding to give Free Press online subscriptions to those that can’t afford one in these extraordinary times — giving new readers the opportunity to see beyond the headlines and connect with other stories about their community.

To those who have made donations, thank you.

To those able to give and share our journalism with others, please Pay it Forward.

The Free Press has shared COVID-19 stories free of charge because we believe everyone deserves access to trusted and critical information during the pandemic.

While we stand by this decision, it has undoubtedly affected our bottom line.

After nearly 150 years of reporting on our city, we don’t want to stop any time soon. With your support, we’ll be able to forge ahead with our journalistic mission.

If you believe in an independent, transparent, and democratic press, please consider subscribing today.

We understand that some readers cannot afford a subscription during these difficult times and invite them to apply for a free digital subscription through our Pay it Forward program.

The Free Press will close this commenting platform at noon on July 14.

We want to thank those who have shared their views over the years as part of this reader engagement initiative.

In the coming weeks, the Free Press will announce new opportunities for readers to share their thoughts and to engage with our staff and each other.

You can comment on most stories on The Winnipeg Free Press website. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or digital subscriber to join the conversation and give your feedback.

Have Your Say

Have Your Say

Comments are open to The Winnipeg Free Press print or digital subscribers only. why?

Have Your Say

Comments are open to The Winnipeg Free Press Subscribers only. why?

By submitting your comment, you agree to abide by our Community Standards and Moderation Policy. These guidelines were revised effective February 27, 2019. Have a question about our comment forum? Check our frequently asked questions.

Advertisement

Advertise With Us